

## Lupin Limited

### Disclosure of related party transactions and balances for the half year ended September 30, 2021 (Consolidated)

#### A. Relationships -

##### Category I: Entity having significant influence over the company:

Lupin Investments Pvt. Limited

##### Category II: Jointly Controlled Entity:

YL Biologics Ltd., Japan

##### Category III: Key Management Personnel (KMP)

Ms. Vinita Gupta	Chief Executive Officer
Mr. Nilesh D. Gupta	Managing Director
Mr. Ramesh Swaminathan	Executive Director, Global CFO & Head Corporate Affairs
Mr. R. V. Satam	Company Secretary

##### Non- Executive Directors

Mrs. Manju D. Gupta	Chairman
Dr. Kamal K. Sharma	Vice Chairman
Mr. Jean-Luc Belingard	Independent Director
Ms. Christine Mundkur	Independent Director
Mr. K. B. S. Anand	Independent Director
Dr. Punita Kumar-Sinha	Independent Director
Mr. Robert Funsten (upto May 9, 2021)	Independent Director
Mr. Mark D. Mcdade	Independent Director

##### Category IV: Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence)

Ms. Kavita Gupta (Daughter of Chairman)  
Dr. Anuja Gupta (Daughter of Chairman)  
Dr. Richa Gupta (Daughter of Chairman)  
Ms. Shefali Nath Gupta (Wife of Managing Director)  
Miss Veda Nilesh Gupta (Daughter of Managing Director)  
Master Neel Deshbandhu Gupta (Son of Managing Director)  
D. B. Gupta (HUF)  
Gupta Family Trust  
Lupin Human Welfare and Research Foundation  
Mata Shree Gomati Devi Jan Seva Nidhi  
Polynova Industries Limited  
Zyma Properties Pvt. Limited  
Shuban Prints  
S N Pharma  
Team Lease Services Limited

**B. Transactions with the related parties:**

(₹ in million)

Sr. No.	Transactions	For the six months ended 30.09.2021
1.	<b>Rent Paid</b> Others	22.4
2.	<b>Expenses Recovered / Rent Received</b> Others	0.8
3.	<b>Remuneration Paid</b> Key Management Personnel	188.9
4.	<b>Purchases of Goods / Materials</b> Jointly Controlled Entity Others	12.2 79.3
5.	<b>Perquisites, Tax borne by the company on exercise of ESOPs &amp; Sitting Fees to Non Executive Directors</b> Key Management Personnel	22.7
6.	<b>Donations Paid</b> Others	86.7
7.	<b>Dividend Paid</b> Entity having significant influence over the Company Key Management Personnel Others	1,336.5 34.4 12.3
8.	<b>Services Received (Expense)</b> Others	45.7
9.	<b>Expenses incurred on our behalf &amp; Other Reimbursements</b> Others	1.9

**C. Balances due from/to the related parties:**

(₹ in million)

Sr. No.	Balances	As at 30.09.2021
1.	<b>Deposits paid under Leave and Licence arrangement for premises</b> Others	29.0
2.	<b>Trade Receivables</b> Jointly Controlled Entity	31.5
3.	<b>Trade Payables</b> Others	4.4
4.	<b>Deposits received under Leave and Licence arrangement for premises</b> Others	0.1

Transactions and balances with Jointly Controlled Entity have been reported at full value.